ReviewImmunology2018
Cancer stem cells as targets for immunotherapy.
Review in Immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas.PloS one · 2019Pooled it
- Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses.Signal transduction and targeted therapy · 2026Review
- The bibliometric and visualized analysis on cancer stem cells in the early 21st century.International journal of surgery (London, England) · 2026Review
- WNT pathway inhibition sensitizes HAT1-high lung cancers to treatment with PD-1 inhibitors.Cancer cell international · 2025Article
- Immunotherapeutic Strategies Targeting Breast Cancer Stem Cells.Current oncology (Toronto, Ont.) · 2024Review
- Comprehensive analysis of m6A modification in immune infiltration, metabolism and drug resistance in hepatocellular carcinoma.Cancer cell international · 2024Article
- MiR-21-5p Modulates Cisplatin-Resistance of CD44+ Gastric Cancer Stem Cells Through Regulating the TGF-β2/SMAD Signaling Pathway.International journal of general medicine · 2024Article
- Extracellular vesicles and cancer stem cells: a deadly duo in tumor progression.Oncology reviews · 2024Review
- ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights.Frontiers in immunology · 2024Review
- Biomarkers and targeted therapy for cancer stem cells.Trends in pharmacological sciences · 2024Review
- Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.Human vaccines & immunotherapeutics · 2023Article
- Update on immune-based therapy strategies targeting cancer stem cells.Cancer medicine · 2023Review
- Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.Genes & diseases · 2023Review
- Advances of nanotechnology applied to cancer stem cells.World journal of stem cells · 2023Review
- Therapeutic implications of cancer stem cells in prostate cancer.Cancer biology & medicine · 2023Review
- Cancer stem cells markers in ovarian cancer: Clinical and therapeutic significance (Review).Oncology letters · 2022Review
- ABCG2, CD44 and SOX9 are increased with the acquisition of drug resistance and involved in cancer stem cell activities in head and neck squamous cell carcinoma cells.Experimental and therapeutic medicine · 2022Article
- Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems.Stem cell reviews and reports · 2022Review
- SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling.The Journal of clinical investigation · 2022Article
- Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.Cancer immunology, immunotherapy : CII · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current cancer therapies target the bulk of the tumour, while a population of highly resistant tumour cells may be able to repopulate the tumour and metastasize to new sites. Cancer cells with such stem cell-like characteristics can be identified based on their phenotypical and/or functional features which may open up ways for their targeted elimination. In this review we discuss potential off-target effects of inhibiting cancer stem-cell self-renewal pathways on immune cells, and summarize some recent immunological studies specifically targeting cancer stem cells based on their unique antigen expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.